Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17334386 | 0.92 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2MEN1 | |
| SCHEMBL17334358 | 0.80 | ALDH1A1 (0.55) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL17340779 | 0.79 | CDC7 (0.38) | — | |
| SCHEMBL9938533 | 0.75 | ALDH1A1 (0.69) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2MEN1 | |
| SCHEMBL9941025 | 0.75 | ALDH1A1 (0.66) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2MEN1 | |
| SCHEMBL4494006 | 0.70 | ALDH1A1 (0.82) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2MEN1 | |
| SCHEMBL17341019 | 0.69 | CDC7 (0.36) | — | |
| SCHEMBL17340784 | 0.69 | ALDH1A1 (0.60) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2MEN1 | |
| SCHEMBL24687615 | 0.69 | ALDH1A1 (0.57) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2MEN1 | |
| SCHEMBL2521926 | 0.68 | SMN1; SMN2 (0.80) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676782-B2 | Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of metabotropic glutamate receptor 3 | VANDERBILT UNIVERSITY (US) | 2017-06-13 | — | — | US | disclosed |
| US-20150361081-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 3 | VANDERBILT UNIVERSITY | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361081-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 3 | GRM3, GRM1, GRIN3A | ALDH1A1 4735/4885CYP1A2 4630/4885CYP2C19 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.